Abcam, ab220163, Anti-YTHDF2 antibody [EPR20318]

Size: 100µL / 1mL
Anti-YTHDF2 antibody [EPR20318] (ab220163) is a rabbit monoclonal antibody detecting YTHDF2 in Western Blot, IP . Suitable for Human, Mouse, Rat . - KO validated for confirmed specificity - Biophysical QC for unrivalled batch-batch consistency - Over 50 publications
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR20318,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What is this antibody validated in?
Anti-YTHDF2 antibody [EPR20318] (ab220163) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunoprecipitation (IP) in Human, Mouse, Rat samples.
What is the molecular weight of YTHDF2?
Anti-YTHDF2 [EPR20318] (ab220163) specifically detects a band for YTHDF2 (UniProt: Q9Y5A9) at a molecular weight of 62kDa.
Trusted by the scientific community
Anti-YTHDF2 [EPR20318] (ab220163) was first used in a scientific publication in 2018 and has been cited over 50 times in peer-reviewed journals.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl.
Discover our selection of trial-size antibodies
Specificity confirmed
The specificity of Anti-YTHDF2 antibody [EPR20318] (ab220163) has been confirmed by Western blot testing in YTHDF2 Knockout mESC cells.
Other related products
We have a range of other formats of antibody clone [EPR20318] also available for your convenience: ab220163, Carrier free -
ab245129
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
YTHDF2 also known as YTH domain family member 2 mechanically functions as a reader of N6-methyladenosine (m6A)-modified RNA. YTHDF2 binds to these m6A-modified sites on messenger RNA leading to degradation of these transcripts. This protein acts in the cytoplasm and has a molecular weight of approximately 65 kDa. YTHDF2 is highly expressed in various tissues including in the brain liver and reproductive organs.
Biological function summary
YTHDF2 plays a critical role in regulating mRNA stability and decay impacting gene expression dynamically. It acts as an important regulator in processes such as cell differentiation and response to stress. YTHDF2 does not seem to form a complex but interacts with other proteins to fulfill its regulatory functions. Importantly these interactions help manage the cellular RNA cycle maintaining proper cellular physiology.
Pathways
YTHDF2 integrates into the mRNA surveillance pathway and influences processes such as the circadian rhythm and immune response. It works with proteins such as DCP1/2 which are part of the mRNA decay pathway to ensure rapid turnover of target mRNAs. YTHDF2's control over transcript degradation connects it with RNA-processing machinery impacting pathways reliant on precise proteomic modulation.
Abnormal YTHDF2 function can contribute to cancer and metabolic disorders. In cancer its interaction with tumor suppressor proteins like p53 alters transcript levels important for cancer cell survival. In metabolic disorders YTHDF2's effect on mRNA turnover can influence pathways involving insulin secretion. YTHDF2's involvement in these diseases suggests it as a potential target for therapeutic intervention.